NanoViricides to showcase lead drug asset’s progress at EF Hutton Annual Global Conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
1,514$
-1,66%
Echtzeit-Aktienkurs Nanoviricides Inc.
Bid:
Ask:
Nachrichten zur Nanoviricides Inc. Aktie
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the...…
NanoViricides drug asset shows ‘superior antiviral effects’ against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses. The...…
NanoViricides completes Phase 1 trial for respiratory viral infection candidate
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…
NanoViricides completes Phase 1 trial of lead asset NV-387
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…